Lilly’s revenue soars 48%, driven by demand for its GLP-1s
MarketWatch· Jaimy Lee· Aug 5, 2026 · 11:17 AM
Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.
This is a summary. Read the complete story at MarketWatch below.
Read full article at MarketWatchRelated Stories
marketsabout 3 hours ago
To win the humanoid-robots race, the U.S. needs this critical machine component that’s hard to find
Humanoid robots have the potential to revolutionize life as we know it — but the U.S. does not have a supply chain that can produce key parts.
MarketWatch
marketsabout 4 hours ago
I’m in my 20s and keep getting laid off. Should I invest in my employer’s 401(k) or look into other options?
“I have lost faith that the traditional career spanning decades at one company even exists anymore.”
MarketWatch
marketsabout 5 hours ago
TV dinner overload? The frozen-food aisle may be too crowded for its own good.
Industry giant Conagra Brands has so many frozen-food items that they’re competing against each other, an analyst says.
MarketWatch